NovoCure (NVCR) Net Income Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 62.29% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 343.24% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 2.38% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -10.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.27% |
| Dec 31, 2025 | 13.08% |
| Sep 30, 2025 | -11.93% |
| Jun 30, 2025 | -18.69% |
| Mar 31, 2025 | -94.74% |
| Dec 31, 2024 | -35.57% |
| Sep 30, 2024 | -32.56% |
| Jun 30, 2024 | -31.61% |
| Mar 31, 2024 | -110.97% |
| Dec 31, 2023 | -126.21% |
| Sep 30, 2023 | -94.25% |
| Jun 30, 2023 | -232.30% |
| Mar 31, 2023 | -148.94% |
| Dec 31, 2022 | -120.75% |
| Sep 30, 2022 | -150.77% |
| Jun 30, 2022 | -166.39% |
| Mar 31, 2022 | 27.41% |
| Dec 31, 2021 | -19.18% |
| Sep 30, 2021 | -3.92% |
| Jun 30, 2021 | 1.90% |
| Mar 31, 2021 | 41.60% |
| Dec 31, 2020 | 34.80% |
| Sep 30, 2020 | 41.07% |
| Jun 30, 2020 | 27.61% |
| Mar 31, 2020 | 30.43% |
| Dec 31, 2019 | -58.32% |
| Sep 30, 2019 | 27.19% |
| Jun 30, 2019 | 68.49% |
| Mar 31, 2019 | 30.01% |
| Dec 31, 2018 | 21.99% |
| Sep 30, 2018 | 23.40% |
| Jun 30, 2018 | 19.16% |
| Mar 31, 2018 | 3.79% |
| Dec 31, 2017 | -32.18% |
| Sep 30, 2017 | 14.38% |